The week in industry: Global medicine spending to exceed US$1.5 trillion by 2023

This week: First success announced from collaboration to tackle issues in early stage R&D, three big pharmaceutical manufacturers are asked to explain the skyrocketing insulin prices and the European Commission has approved a new treatment for relapsed ovarian cancer.